Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Tivic Health Systems Inc (TIVC) delivers innovative bioelectronic solutions through its non-invasive microcurrent therapies, most notably the ClearUP Sinus Relief device. This page provides direct access to all official corporate announcements, financial disclosures, and therapeutic development updates.
Investors and healthcare professionals will find chronologically organized press releases covering regulatory milestones, clinical study results, and partnership agreements. Our repository includes quarterly earnings reports, product launch details, and scientific validation updates – all essential for understanding TIVC's position in the health technology sector.
Key focus areas include advancements in bioelectronic treatment platforms, market expansion initiatives, and peer-reviewed research findings. Content is rigorously verified to ensure alignment with SEC filings and medical device regulations. Bookmark this page for efficient tracking of material developments affecting TIVC's therapeutic innovations and business trajectory.
Tivic Health, trading under the ticker TIVC, will announce its Q1 2024 financial results on May 15th via a pre-recorded conference call and webcast. The call is scheduled for 1:30 PM PT / 4:30 PM ET. The company specializes in developing and commercializing bioelectronic medicine. Stakeholders can join the call using the provided toll-free and international numbers, or view the webcast online.
Tivic Health Systems announced the closing of a $4.0 million public offering. The offering included 4,710,000 shares of common stock, Series A warrants for 4,710,000 shares, and Series B warrants for 7,065,000 shares, all priced at $0.85 per share. The Series A warrants are exercisable immediately and expire in one year, while the Series B warrants also exercisable immediately, expire in five years. Maxim Group served as the sole placement agent. The gross proceeds before fees and expenses amounted to $4.0 million. The offering was made through a registration statement declared effective by the SEC on May 9, 2024. Investors can access the final prospectus on the SEC website.
Tivic Health Systems, a health tech company, announced the pricing of a public offering consisting of common stock and warrants, expecting to raise approximately $4.0 million. The offering includes Series A and Series B warrants with different terms and exercise prices. The closing is scheduled for May 13, 2024, subject to customary conditions. Maxim Group is the sole placement agent for the offering.
Tivic Health announced successful completion of a pilot research study showing the effectiveness of their non-invasive vagus nerve stimulation approach in inducing responses in the autonomic, cardiac, and central nervous systems. Results included a 97% increase in heart rate variability and changes in brain activity consistent with reduced arousal and anxiety. The company aims to improve bioelectronic medicine and expand into new market segments. VNS is a growing market with significant potential in various medical conditions.
FAQ
What is the current stock price of Tivic Health Systems (TIVC)?
What is the market cap of Tivic Health Systems (TIVC)?
